Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of... see more

Recent & Breaking News (NDAQ:CTXR)

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

PR Newswire 16 hours ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

PR Newswire 4 days ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

PR Newswire 7 days ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR(TM) in Cancer Patients with Recurrent Solid Tumors

PR Newswire 11 days ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire September 5, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR(TM) (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

PR Newswire September 5, 2024

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Accesswire August 13, 2024

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

PR Newswire August 12, 2024

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

PR Newswire August 12, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

PR Newswire August 12, 2024

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

GlobeNewswire August 9, 2024

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR(TM) (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

PR Newswire August 8, 2024

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

GlobeNewswire August 5, 2024

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

PR Newswire August 5, 2024

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Newsfile July 18, 2024

Analysts Hunt for Undervalued Biotech Stocks

Newsfile July 17, 2024

Bloodstream Infections - From Threats to Solutions

Newsfile July 11, 2024

Biopharma Stocks Transformative Innovation for the Future of Health

Newsfile July 11, 2024

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

PR Newswire July 10, 2024

Sidoti Events, LLC's Virtual June Small-Cap Conference

Accesswire June 11, 2024